PT - JOURNAL ARTICLE AU - Klann, Eric TI - Thwarting Dyskinesia by Targeting mTORC1 AID - 10.1126/scisignal.280pe42 DP - 2009 Jul 21 TA - Science Signaling PG - pe42--pe42 VI - 2 IP - 80 4099 - http://stke.sciencemag.org/content/2/80/pe42.short 4100 - http://stke.sciencemag.org/content/2/80/pe42.full SO - Sci. Signal.2009 Jul 21; 2 AB - In a mouse model of Parkinson’s disease, new evidence shows that l-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons. Moreover, blockade of a specific type of mTOR signaling (mTORC1) prevents the development of dyskinesia, but not the antiakinetic benefits produced by l-DOPA. Thus, mTORC1 may be a viable therapeutic target for dyskinesia caused by l-DOPA treatment in patients with Parkinson’s disease.